IDEXX Laboratories, Inc. (IDXX)

NMS – Real Time Price. Currency in USD

572.59

-14.05 (-2.39%)

Market open: Aug 12, 2026, 1:15 PM EDT

586.65

+0.01 (0.00%)

Previous after-hours: Aug 11, 2026, 7:49 PM EDT

12.08.2026

Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

11.08.2026

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.

08.08.2026

IDEXX Laboratories: Worth The Premium

IDEXX Laboratories remains a buy, supported by a durable moat, strong recurring revenue, and a long-term international growth runway. Recent Q2 2026 results showed 9% organic revenue growth, EPS guidance raised to $14.69–14.94, and robust expansion of diagnostic offerings. Installed base growth for core machines is moderating in the US but remains early-stage internationally, underpinning multi-decade expansion potential.

06.08.2026

Here is Why Growth Investors Should Buy Idexx (IDXX) Now

Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.

04.08.2026

IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market

IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.

04.08.2026

IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript

04.08.2026

IDEXX Laboratories Q2 Earnings Call Highlights

IDEXX Laboratories NASDAQ: IDXX reported second-quarter 2026 revenue growth of approximately 10% on a reported basis and 9% organically, driven by companion animal diagnostics, water and livestock, poultry and dairy businesses. The company raised its full-year revenue and earnings outlook, citing strong recurring diagnostics revenue, product-cost benefits and continued momentum from new product introductions.

Videos

No Data

There is no data to display

Press releases

11.08.2026

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.

04.08.2026

IDEXX Laboratories Announces Second Quarter Results

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced second quarter results. Second Quarter Results The Company reports revenues of $1,217 million for the second quarter of 2026, an increase of 10% as reported and 9% organic, driven by Companion Animal Group ("CAG") growth of 9% as reported and organic, Water revenue growth of 15% as reported and 13% organic, and LPD revenue growth of 11% as reported and 9% org.

IDEXX Laboratories, Inc. (IDXX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

IDEXX Laboratories, Inc. (IDXX)

Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

IDEXX Laboratories: Worth The Premium

Here is Why Growth Investors Should Buy Idexx (IDXX) Now

IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market

IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript

IDEXX Laboratories Q2 Earnings Call Highlights

Videos

No Data

Press releases

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

IDEXX Laboratories Announces Second Quarter Results

Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

IDEXX Laboratories: Worth The Premium

Here is Why Growth Investors Should Buy Idexx (IDXX) Now

IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market

IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript

IDEXX Laboratories Q2 Earnings Call Highlights

Videos

No Data

Press releases

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

IDEXX Laboratories Announces Second Quarter Results

Search stocks

IDEXX Laboratories, Inc. (IDXX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

IDEXX Laboratories, Inc. (IDXX)

Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

IDEXX Laboratories: Worth The Premium

Here is Why Growth Investors Should Buy Idexx (IDXX) Now

IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market

IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript

IDEXX Laboratories Q2 Earnings Call Highlights

Videos

No Data

Press releases

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

IDEXX Laboratories Announces Second Quarter Results

Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

IDEXX Laboratories: Worth The Premium

Here is Why Growth Investors Should Buy Idexx (IDXX) Now

IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market

IDEXX Laboratories, Inc. (IDXX) Q2 2026 Earnings Call Transcript

IDEXX Laboratories Q2 Earnings Call Highlights

Videos

No Data

Press releases

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

IDEXX Laboratories Announces Second Quarter Results